- Home
- NDLS vs XLO Comparison
NDLS vs XLO Comparison
Compare NDLS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- XLO
- Stock Information
- Founded
- NDLS 1995
- XLO 2016
- Country
- NDLS United States
- XLO United States
- Employees
- NDLS N/A
- XLO N/A
- Industry
- NDLS Restaurants
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- XLO Health Care
- Exchange
- NDLS Nasdaq
- XLO Nasdaq
- Market Cap
- NDLS 35.4M
- XLO 42.2M
- IPO Year
- NDLS 2013
- XLO 2021
- Fundamental
- Price
- NDLS $0.71
- XLO $0.69
- Analyst Decision
- NDLS Strong Buy
- XLO Buy
- Analyst Count
- NDLS 2
- XLO 1
- Target Price
- NDLS $3.00
- XLO $4.00
- AVG Volume (30 Days)
- NDLS 201.5K
- XLO 625.2K
- Earning Date
- NDLS 08-06-2025
- XLO 08-07-2025
- Dividend Yield
- NDLS N/A
- XLO N/A
- EPS Growth
- NDLS N/A
- XLO N/A
- EPS
- NDLS N/A
- XLO N/A
- Revenue
- NDLS $495,670,000.00
- XLO $9,274,000.00
- Revenue This Year
- NDLS $5.37
- XLO $300.08
- Revenue Next Year
- NDLS $0.68
- XLO $1.87
- P/E Ratio
- NDLS N/A
- XLO N/A
- Revenue Growth
- NDLS N/A
- XLO N/A
- 52 Week Low
- NDLS $0.55
- XLO $0.62
- 52 Week High
- NDLS $1.83
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- NDLS 41.91
- XLO 46.69
- Support Level
- NDLS $0.55
- XLO $0.66
- Resistance Level
- NDLS $0.82
- XLO $0.70
- Average True Range (ATR)
- NDLS 0.07
- XLO 0.03
- MACD
- NDLS -0.00
- XLO 0.01
- Stochastic Oscillator
- NDLS 50.25
- XLO 81.13
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).